The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

Shannon N. Westin, MD, MPH, FACOG, discusses future directions in endometrial cancer.

Michael Wang, MD, discusses unique properties of the investigational CAR T-cell therapy KTE-X19 in relapsed/refractory mantle cell lymphoma.

Nizar M. Tannir, MD, FACP, discusses the 42-month follow-up results from the CheckMate-214 trial in advanced renal cell carcinoma and provides perspective on other approved combinations in the frontline setting.

In our exclusive interview, Dr. Hortobagyi shares his journey in the development of anthracyclines and taxanes, biphosphonates, and gene therapies in breast cancer, some of the challenges he has encountered along the way, and what he hopes to tackle in the rest of his monumental career.

Hoping to minimize the off-target effects associated with radiation in patients with oropharyngeal cancer, investigators are testing the hypothesis that intensitymodulated proton therapy can deliver doses as effectively as the current standard of care with less damage to surrounding tissue.

Ryan W. Huey, MD, assistant professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the landscape of hepatocellular carcinoma (HCC).

Curtis A. Pettaway, MD, professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the prevalence of germline mutations in diverse populations with prostate cancer.

Rashmi Murthy, MD, MBE, discusses the data that led to the approval of the tucatinib triplet, the clinical implications of the approval on practice, and the next steps for research with the agent.

Ahmed O. Kaseb, MD, discusses the safety profile of the combination of atezolizumab and bevacizumab in hepatocellular carcinoma.

Ryan W. Huey, MD, highlights the evolving treatment options in the hepatocellular carcinoma paradigm and discusses challenges and next steps in the field.

Naval G. Daver, MD, discusses the impact of COVID-19 on stem cell transplant for patients with hematologic malignancies and other measures put into place to prevent patients from infection.

Michael A. Choti, MD, discusses the role of upfront surgery in pancreatic adenocarcinoma.

Naveen Pemmaraju, MD, discusses the need for collaboration when diagnosing and treating patients with myelofibrosis.

Matthew H.G. Katz, MD, FACS, discusses the benefit of neoadjuvant chemotherapy in patients with pancreatic cancer.

Ruben Mesa, MD, and his patient Antje Hjerpe, who has been living with essential thrombocythemia for 35 years, share the challenges in diagnosing ET, the current state of treatment and ongoing research efforts, and resources Mesa recommends on educating both physicians and patients on myeloproliferative neoplasms and components of care.

Ruben Mesa, MD, discusses unanswered questions regarding JAK inhibitors in myelofibrosis.

Michael Wang, MD, discusses the implications of the ZUMA-2 trial for patients with relapsed/refractory mantle cell lymphoma and other targeted therapies on the horizon.

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses ongoing research in mantle cell lymphoma (MCL).

Findings from the pivotal phase II ZUMA-2 trial of KTE-X19 as a treatment for adult patients with relapsed/refractory mantle cell lymphoma were published in the New England Journal of Medicine, as the FDA considers a biologics license application for the CAR T-cell therapy for an approval in this setting.

We had the pleasure of speaking with Jaffer Ajani, MD, who discussed some of the investigational HER2-targeted treatment strategies with trastuzumab, antibody-drug conjugates, and bispecific antibodies that are under investigation in gastrointestinal malignancies.

A subset of patients with metastatic castration-resistant prostate cancer who have low tumor mutational burden may benefit from checkpoint inhibition with ipilimumab if the tumor has a high density of CD8-positive T cells and increased interferon-interferon gamma signaling.

Shubham Pant, MD, discusses choosing therapy for the frontline and beyond in pancreatic cancer.

Matthew T. Campbell, MD, discusses the evolving treatment options in the renal cell carcinoma paradigm.

Ahmed O. Kaseb, MD, a professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses research with targeted therapy in hepatocellular carcinoma (HCC).

Kanwal Raghav, MBBS, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses ongoing research with immunotherapy and targeted therapy in colorectal cancer (CRC).

Michael J. Overman, MD, discusses factors to consider when choosing between regorafenib and TAS-102 in the third-line treatment of patients with colorectal cancer.

Douglas A. Nelson, MD, discusses results from the CheckMate-142 in metastatic colorectal cancer.

Jonathan Mizrahi, MD, discusses optimal sequencing in patients with BRAF V600E-mutant metastatic colorectal cancer.

Douglas A. Nelson, MD, discusses the quality-of-life data from the phase III BEACON CRC trial in metastatic colorectal cancer.

Phat Le, MD, discusses the need for aggressive therapeutic approaches in oligometastatic colorectal cancer.